Matt O'Brien
Stock Analyst at Piper Sandler
(2.35)
# 2,572
Out of 5,116 analysts
194
Total ratings
46.95%
Success rate
-2.8%
Average return
Main Sectors:
Stocks Rated by Matt O'Brien
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KMTS Kestra Medical Technologies | Maintains: Overweight | $27 → $30 | $27.15 | +10.50% | 2 | Dec 12, 2025 | |
| TELA TELA Bio | Reiterates: Neutral | $2 → $1.25 | $1.14 | +9.65% | 7 | Nov 14, 2025 | |
| SI Shoulder Innovations | Reiterates: Overweight | $18 | $15.25 | +18.03% | 2 | Nov 12, 2025 | |
| CNMD CONMED | Maintains: Overweight | $68 → $55 | $40.80 | +34.80% | 14 | Nov 6, 2025 | |
| PRCT PROCEPT BioRobotics | Reiterates: Overweight | $55 → $50 | $32.41 | +54.27% | 5 | Nov 5, 2025 | |
| DXCM DexCom | Maintains: Overweight | $100 → $75 | $67.57 | +11.00% | 13 | Oct 31, 2025 | |
| ATEC Alphatec Holdings | Reiterates: Overweight | $20 → $25 | $20.97 | +19.25% | 4 | Oct 31, 2025 | |
| TMDX TransMedics Group | Maintains: Overweight | $145 → $140 | $124.20 | +12.72% | 13 | Oct 30, 2025 | |
| BBNX Beta Bionics | Reiterates: Overweight | $26 → $32 | $31.86 | +0.44% | 2 | Oct 29, 2025 | |
| ITGR Integer Holdings | Maintains: Overweight | $155 → $82 | $78.88 | +3.96% | 3 | Oct 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $22 | $17.34 | +26.87% | 3 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $18 | $13.71 | +31.29% | 1 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $30 → $14 | $22.35 | -37.36% | 9 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $80 | $88.41 | -9.51% | 12 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $12 | $7.42 | +61.73% | 9 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $180 → $165 | $116.21 | +41.98% | 10 | Apr 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5.5 → $3.5 | $8.82 | -60.32% | 7 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $255 → $140 | $122.76 | +14.04% | 5 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $285 → $310 | $288.63 | +7.40% | 8 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $250 → $330 | $316.97 | +4.11% | 13 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $50 | $40.33 | +23.98% | 3 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $40 → $16 | $23.35 | -31.48% | 7 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $95 → $115 | $96.06 | +19.72% | 3 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $9 → $12 | $3.44 | +248.84% | 7 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $380 → $420 | $354.22 | +18.57% | 12 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $85 → $90 | $96.52 | -6.76% | 9 | Aug 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $25 | $20.36 | +22.79% | 1 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3.5 → $3 | $1.07 | +180.37% | 2 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4 → $4.5 | $3.44 | +30.81% | 2 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $90.77 | - | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $15 | $4.32 | +247.22% | 1 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $93 → $109 | $82.62 | +31.63% | 1 | Feb 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $100 → $80 | $19.38 | +312.80% | 1 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $12 | $6.23 | +92.62% | 1 | Jun 24, 2020 |
Kestra Medical Technologies
Dec 12, 2025
Maintains: Overweight
Price Target: $27 → $30
Current: $27.15
Upside: +10.50%
TELA Bio
Nov 14, 2025
Reiterates: Neutral
Price Target: $2 → $1.25
Current: $1.14
Upside: +9.65%
Shoulder Innovations
Nov 12, 2025
Reiterates: Overweight
Price Target: $18
Current: $15.25
Upside: +18.03%
CONMED
Nov 6, 2025
Maintains: Overweight
Price Target: $68 → $55
Current: $40.80
Upside: +34.80%
PROCEPT BioRobotics
Nov 5, 2025
Reiterates: Overweight
Price Target: $55 → $50
Current: $32.41
Upside: +54.27%
DexCom
Oct 31, 2025
Maintains: Overweight
Price Target: $100 → $75
Current: $67.57
Upside: +11.00%
Alphatec Holdings
Oct 31, 2025
Reiterates: Overweight
Price Target: $20 → $25
Current: $20.97
Upside: +19.25%
TransMedics Group
Oct 30, 2025
Maintains: Overweight
Price Target: $145 → $140
Current: $124.20
Upside: +12.72%
Beta Bionics
Oct 29, 2025
Reiterates: Overweight
Price Target: $26 → $32
Current: $31.86
Upside: +0.44%
Integer Holdings
Oct 24, 2025
Maintains: Overweight
Price Target: $155 → $82
Current: $78.88
Upside: +3.96%
Oct 10, 2025
Maintains: Overweight
Price Target: $30 → $22
Current: $17.34
Upside: +26.87%
Aug 18, 2025
Initiates: Overweight
Price Target: $18
Current: $13.71
Upside: +31.29%
Aug 7, 2025
Downgrades: Neutral
Price Target: $30 → $14
Current: $22.35
Upside: -37.36%
May 9, 2025
Maintains: Overweight
Price Target: $100 → $80
Current: $88.41
Upside: -9.51%
May 9, 2025
Maintains: Overweight
Price Target: $20 → $12
Current: $7.42
Upside: +61.73%
Apr 15, 2025
Maintains: Overweight
Price Target: $180 → $165
Current: $116.21
Upside: +41.98%
Mar 6, 2025
Maintains: Neutral
Price Target: $5.5 → $3.5
Current: $8.82
Upside: -60.32%
Feb 28, 2025
Downgrades: Neutral
Price Target: $255 → $140
Current: $122.76
Upside: +14.04%
Feb 21, 2025
Maintains: Overweight
Price Target: $285 → $310
Current: $288.63
Upside: +7.40%
Feb 19, 2025
Reiterates: Overweight
Price Target: $250 → $330
Current: $316.97
Upside: +4.11%
Feb 13, 2025
Maintains: Overweight
Price Target: $40 → $50
Current: $40.33
Upside: +23.98%
Feb 12, 2025
Maintains: Neutral
Price Target: $40 → $16
Current: $23.35
Upside: -31.48%
Feb 3, 2025
Maintains: Overweight
Price Target: $95 → $115
Current: $96.06
Upside: +19.72%
Nov 8, 2024
Reiterates: Neutral
Price Target: $9 → $12
Current: $3.44
Upside: +248.84%
Oct 30, 2024
Reiterates: Overweight
Price Target: $380 → $420
Current: $354.22
Upside: +18.57%
Aug 21, 2024
Maintains: Neutral
Price Target: $85 → $90
Current: $96.52
Upside: -6.76%
Mar 28, 2024
Initiates: Overweight
Price Target: $25
Current: $20.36
Upside: +22.79%
Nov 10, 2023
Maintains: Neutral
Price Target: $3.5 → $3
Current: $1.07
Upside: +180.37%
Aug 11, 2023
Maintains: Overweight
Price Target: $4 → $4.5
Current: $3.44
Upside: +30.81%
Mar 10, 2023
Upgrades: Overweight
Price Target: n/a
Current: $90.77
Upside: -
Feb 24, 2023
Initiates: Overweight
Price Target: $15
Current: $4.32
Upside: +247.22%
Feb 11, 2021
Maintains: Overweight
Price Target: $93 → $109
Current: $82.62
Upside: +31.63%
Jan 29, 2021
Downgrades: Neutral
Price Target: $100 → $80
Current: $19.38
Upside: +312.80%
Jun 24, 2020
Initiates: Overweight
Price Target: $12
Current: $6.23
Upside: +92.62%